Risk of cardiovascular disease: The effects of diabetes and anti-diabetic drugs - A nested case-control study

International Journal of Cardiology

Volumn 178, Issue , 2016, Pages 292-296

  Gejl, Michael ^a,b,c   Starup Linde, Jakob ^c,d   Scheel Thomsen, Jan ^e   Gregersen, Soeren ^c   Vestergaard, Peter ^d,e  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biguanides; Cardiovascular disease; GLP 1; Glucagon like peptide 1; Liraglutide; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIRAGLUTIDE; HYPOGLYCEMIC AGENTS;

AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; DENMARK; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG USE; FEMALE; HEART FAILURE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; RISK REDUCTION; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; MIDDLE AGED; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84916607012     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.11.096     Document Type: Article

References (29)

1. N.J. Morrish, S.L. Wang, L.K. Stevens, J.H. Fuller, and H. Keen Mortality and causes of death in the WHO multinational study of vascular disease in diabetes Diabetologia 44 Suppl. 2 2001 S14 S21
2. S.J. Haffner, and H. Cassells Hyperglycemia as a cardiovascular risk factor Am. J. Med. 115 Suppl. 8A 2003 6S 11S
3. A. Brown, L.R. Reynolds, and D. Bruemmer Intensive glycemic control and cardiovascular disease: an update Nat. Rev. Cardiol. 7 2010 369 375
4. N.-S.S. Investigators, S. Finfer, D.R. Chittock, S.Y. Su, D. Blair, and D. Foster Intensive versus conventional glucose control in critically ill patients N. Engl. J. Med. 360 2009 1283 1297
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 854 865
6. J. Sivertsen, J. Rosenmeier, J.J. Holst, and T. Vilsboll The effect of glucagon-like peptide 1 on cardiovascular risk Nat. Rev. Cardiol. 9 2012 209 222
7. J. Lonborg, H. Kelbaek, N. Vejlstrup, H.E. Botker, W.Y. Kim, and L. Holmvang Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia Circ. Cardiovasc. Interv. 5 2012 288 295
8. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, and G.L. Bakris Alogliptin after acute coronary syndrome in patients with type 2 diabetes N. Engl. J. Med. 369 2013 1327 1335
9. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, and B. Hirshberg Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N. Engl. J. Med. 369 2013 1317 1326
10. T.F. Andersen, M. Madsen, J. Jorgensen, L. Mellemkjoer, and J.H. Olsen The Danish National Hospital Register. A valuable source of data for modern health sciences Dan. Med. Bull. 46 1999 263 268
11. J.S.-T.J. Starup-Linde, M. Gejl, P. Vestergaard, and S. Gregersen Liraglutide and insulin are associated with a decreased risk of acute myocardial infarction in type 2 diabetes mellitus patients J. Diabetes Metab. 2014 10.4172/2155-6156.1000389
12. J.K. Kristensen, A. Sandbaek, J.F. Lassen, F. Bro, and T. Lauritzen Use and validation of public data files for identification of the diabetic population in a Danish county Dan. Med. Bull. 48 2001 33 37
13. C.S. Fox, L. Sullivan, and R.B. Fau-D'Agostino Sr. D'Agostino Rb Sr Fau-Wilson PWF, Wilson PW The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study, Diabetes Care 27 2004 704 708
14. W.P. Castelli Epidemiology of coronary heart disease: the Framingham study Am. J. Med. 76 1984 4 12
15. J.B. Buse, H.N. Ginsberg, G.L. Bakris, N.G. Clark, F. Costa, and R. Eckel Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care 30 2007 162 172
16. A. Avogaro, C. Giorda, M. Maggini, E. Mannucci, R. Raschetti, and F. Lombardo Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location Diabetes Care 30 2007 1241 1247
17. A. Girach, and L. Vignati Diabetic microvascular complications - can the presence of one predict the development of another? J. Diabet. Complicat. 20 2006 228 237
18. J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, and M. Verschuren European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur. Heart J. 33 2012 1635 1701
19. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, and S.J. Livingstone Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
20. Heart Protection Study Collaborative G MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
21. C. Lamanna, M. Monami, N. Marchionni, and E. Mannucci Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials Diabetes Obes. Metab. 13 2011 221 228
22. K.J. Mather, S. Verma, and T.J. Anderson Improved endothelial function with metformin in type 2 diabetes mellitus J. Am. Coll. Cardiol. 37 2001 1344 1350
23. B. Hemmingsen, S.S. Lund, J. Wetterslev, and A. Vaag Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes Eur. J. Endocrinol. 161 2009 1 9
24. G. Anfossi, I. Russo, K. Bonomo, and M. Trovati The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus Curr. Vasc. Pharmacol. 8 2010 327 337
25. J.E. Campbell, and D.J. Drucker Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab. 17 2013 819 837
26. M. Gejl, J. Rungby, B. Brock, and A. Gjedde At centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose Basic Clin. Pharmacol. Toxicol. 115 2014 162 171
27. J. Hansen, B. Brock, H.E. Botker, A. Gjedde, J. Rungby, and M. Gejl Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited Rev. Endocr. Metab. Disord. 15 2014 219 231
28. M. Monami, F. Cremasco, C. Lamanna, C. Colombi, C.M. Desideri, and I. Iacomelli Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials Exp. Diabetes Res. 2011 2011 215764
29. J.H. Best, B.J. Hoogwerf, W.H. Herman, E.M. Pelletier, D.B. Smith, and M. Wenten Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database Diabetes Care 34 2011 90 95